Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PNMT | P11086 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | MMP14 | P50281 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5261400 | 1.00 | TAAR1 (0.49) | TAAR1SLC6A2MAOASLC6A4SLC6A3 | |
| SCHEMBL5311932 | 1.00 | TAAR1 (0.49) | TAAR1SLC6A2MAOASLC6A4SLC6A3 | |
| SCHEMBL5914073 | 1.00 | TAAR1 (0.49) | TAAR1SLC6A2MAOASLC6A4SLC6A3 | |
| SCHEMBL665619 | 0.84 | GPR139 (0.46) | OPRK1MEN1MAPTKMT2AEPHX2 | |
| SCHEMBL5502273 | 0.81 | TAAR1 (0.41) | TAAR1SLC6A2MAOASLC6A4SLC6A3 | |
| SCHEMBL14395967 | 0.81 | CTSK (0.47) | MAPT | |
| SCHEMBL5948117 | 0.81 | NPC1 (0.51) | TAAR1SIGMAR1MEN1KMT2A | |
| SCHEMBL5914427 | 0.81 | NPC1 (0.51) | TAAR1SIGMAR1MEN1KMT2A | |
| SCHEMBL4001568 | 0.81 | NPC1 (0.51) | TAAR1SIGMAR1MEN1KMT2A | |
| SCHEMBL5914431 | 0.81 | NPC1 (0.51) | TAAR1SIGMAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836174-B2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-1836174-B1 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-1836174-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC. (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20060247263-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2006-11-02 | — | — | US | disclosed |
| US-20060161001-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2006-07-20 | — | — | US | disclosed |
| WO-2006039718-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2006-04-13 | — | — | WO | disclosed |
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060161001-A1 | Substituted heterocyclic compounds and methods of use | MAPT, MYLK2, IAPP | TAAR1 3279/4885SLC6A2 1465/4885MAOA 2579/4885 |
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | MAPT, MYLK2, IAPP | TAAR1 2950/4885SLC6A2 2321/4885MAOA 2987/4885 |
| US-20060247263-A1 | Substituted heterocyclic compounds and methods of use | MAPT, IAPP, MYLK2 | TAAR1 3572/4885SLC6A2 2055/4885MAOA 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.